• Publications
  • Influence
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma:
PURPOSE The three-drug combination of lenalidomide, bortezomib, and dexamethasone (RVD) has shown significant efficacy in multiple myeloma (MM). The Intergroupe Francophone du Myélome (IFM) decidedExpand
  • 208
  • 7
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
In multiple myeloma, cytogenetic changes are important predictors of patient outcome. In this setting, the most important changes are deletion 17p, del(17p), and translocation of chromosomes 4 andExpand
  • 67
  • 4
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
The prognosis of multiple myeloma is mainly dependent upon chromosomal changes. The 2 major abnormalities driving poor outcome are del(17p) and t(4;14). However, the outcome of these high-riskExpand
  • 57
  • 3
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Overexpression of growth differentiation factor 15 (GDF15) by bone marrow mesenchymal stem cells occurs widely in patients with multiple myeloma, but the pathophysiologic effects of GDF15 in thisExpand
  • 73
  • 2
  • PDF
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.
Key Points There is no correlation between ctDNA and bone marrow for MRD by NGS using only immunoglobulin gene rearrangements in myeloma patients.
  • 24
  • 2
Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?
Growth differentiation factor 15 (GDF15) is a divergent member of the transforming growth factor β family discovered in a broad range of cells, as indicated by the diversity of its nomenclature.Expand
  • 104
  • 1
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
  • 48
  • 1
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognosticExpand
  • 20
  • 1
  • PDF
Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe
Background: High dose melphalan (HDM) with autologous stem cell transplantation (ASCT) is a standard of care for multiple myeloma (MM) patients (pts). To date, no conditioning regimen has proven toExpand
  • 18
  • 1
The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma
Purpose: Although the translocation t(4;14) is supposed to be a primary event in multiple myeloma, we have been surprised to observe that in large relapse series of patients, the t(4;14) can beExpand
  • 13
  • 1
  • PDF
...
1
2
3
4
5
...